To evaluate the potential of CD8 cis-targeted IL2 in the context of adoptive cell therapy, A375 melanoma-bearing NSG mice were treated with human CAR-T cells specific for B7H3 with or without CD8-hIL2 (Supplementary Fig. S4H). This evidence concerns the gene IL2 and melanoma.